Latest news with #MerckKGaA
Yahoo
2 days ago
- Business
- Yahoo
Merck and Veolia Lead in Microfiltration Market with Strategic Moves
The Microfiltration Membrane Market Companies Quadrant offers an in-depth analysis of the global microfiltration segment, spotlighting technological advancements and key market trends. It evaluates over 40 companies, highlighting the top 10 as quadrant leaders. Microfiltration, crucial in industries like food, wastewater, and biotechnology, utilizes membranes with pore sizes from 0.1 to 1.0 microns. Increasing demand in Asia-Pacific and the Middle East & Africa, driven by water scarcity and stringent regulations, presents growth opportunities, though high costs and complexity are challenges. Leading players include Merck KGaA, Sartorius AG, and Veolia, who are advancing through innovation and strategic partnerships. Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Microfiltration Membranes - Company Evaluation Report, 2024" report has been added to Microfiltration Membrane Market Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Microfiltration Membrane Market. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. Over 40 companies were evaluated of which the Top 10 Microfiltration Membrane companies were categorized and recognized as the quadrant is a pressure-driven separation process commonly used to purify or separate macromolecules, colloids, and suspended particles from a solution. Microfiltration membranes typically have nominal pore sizes ranging from 0.1 to 1.0 microns. This process is extensively utilized in the food industry for applications such as clarifying wine, juice, and beer. Additionally, it plays a vital role in wastewater treatment and the separation of plasma from blood for therapeutic and commercial purposes. In the biotechnology sector, microfiltration membranes are essential for applications like cell recycling and harvesting, separating recombinant proteins from cell debris, and purifying process streams. When applied to wastewater treatment, microfiltration delivers high-quality effluents that meet water quality standards, facilitates modular expansion, offers flexible configurations, ensures reliable and robust operation, and minimizes downstream disinfection rising demand for microfiltration membranes in emerging economies across the Asia-Pacific and Middle East & Africa regions is driven by increasing water scarcity, the need for clean water, and the production of high-quality effluents through microfiltration technology. The demand for advanced wastewater treatment solutions that provide efficient, high-quality treated water, along with stringent water treatment regulations, are key market drivers. This growing demand presents an opportunity for manufacturers to expand their businesses. However, the complexity of microfiltration membrane systems, which require a skilled workforce, poses a significant challenge. Additionally, the higher capital and operational costs of microfiltration membranes compared to conventional methods act as a restraint on market 360 Quadrant maps the Microfiltration Membrane companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Microfiltration Membrane quadrant. The top criteria for product footprint evaluation included, by Pore Size (Greater than or equal to 0.8 micron (10, 0.8 micron), Greater than or equal to 0.4 micron (0.65, 0.45) and Greater than or equal to 0.1 micron (0.3, 0.2, 0.1 micron)), by Type (Fluorinated polymers, Cellulosic, Polysulfones, Ceramic and Others), by Filtration Mode (Direct flow filtration and Cross-flow filtration) and Players:Merck KGaA (Germany), Sartorius AG (Germany), Kovalus Separation Solutions (US), Hydranautics (US), Pall Corporation (US), 3M (US), Pentair (UK), Asahi Kasei Corporation (Japan), TORAY INDUSTRIES, INC. (Japan), and Veolia (France). These companies focus on innovation, strategic partnerships, and product development to strengthen their market KGaAMerck KGaA is a frontrunner in the microfiltration membrane market, known for its expansive product portfolio which caters to a diverse range of applications across various industries. The company has consistently invested in R&D to develop cutting-edge membrane technologies. Recent expansions and acquisitions, such as that of Exelead Inc., have enhanced Merck's capabilities in mRNA therapeutics and biopharmaceutical AGSartorius AG stands out due to its focused approach in biopharmaceutical filtration, delivering high-quality solutions that meet stringent compliance and regulatory standards. The company has strategically invested in expanding its manufacturing footprint to cater to increasing demands, particularly in key regions such as Europe and North through its advanced microfiltration solutions, plays a significant role in water and wastewater treatment sectors. Their strong market positioning is supported by continuous innovation and strategic mergers, including the integration with Suez Water Technologies. Veolia's efforts are aimed at providing integrated solutions for municipal and industrial sectors globally, ensuring a robust company positioning in the Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions and Exclusions1.3 Limitations1.4 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Increasing Awareness of Water & Wastewater Treatment3.2.1.2 Stringent Wastewater Regulations3.2.1.3 Selective Separation Technologies3.2.2 Restraints3.2.2.1 Reduced Membrane Performance due to Fouling3.2.2.2 High Capital Cost3.2.3 Opportunities3.2.3.1 Increasing Demand for Water Treatment in Developing Countries3.2.3.2 Rising Scarcity of Freshwater3.2.4 Challenges3.2.4.1 Lifespan and Efficiency of Membranes3.3 Impact of Generative AI3.3.1 Introduction3.3.2 Impact of Gen AI on Microfiltration Membranes Market4 Industry Trends4.1 Introduction4.2 Trends/Disruptions Impacting Customer Business4.3 Value Chain Analysis4.3.1 Raw Material Suppliers4.3.2 Manufacturers4.3.3 Distributors and Retailers4.3.4 End-users4.4 Ecosystem Analysis4.5 Technology Analysis4.5.1 Key Technologies4.5.2 Complementary Technologies4.5.3 Adjacent Technologies4.6 Patent Analysis4.6.1 Methodology4.6.2 Patents Granted Worldwide, 2014-20244.6.3 Patent Publication Trends4.6.4 Insights4.6.5 Legal Status of Patents4.6.6 Jurisdiction Analysis4.6.7 Top Applicants4.6.8 List of Major Patents4.7 Porter's Five Forces Analysis4.7.1 Threat of New Entrants4.7.2 Threat of Substitutes4.7.3 Bargaining Power of Suppliers4.7.4 Bargaining Power of Buyers4.7.5 Intensity of Competitive Rivalry5 Competitive Landscape5.1 Introduction5.2 Key Player Strategies/Right to Win, 2021- 20255.3 Market Share Analysis, 20235.4 Revenue Analysis, 2020-20245.5 Brand Comparison5.6 Company Evaluation Matrix: Key Players, 20235.6.1 Stars5.6.2 Emerging Leaders5.6.3 Pervasive Players5.6.4 Participants5.6.5 Company Footprint: Key Players (2023)5.6.5.1 Company Footprint5.6.5.2 Region Footprint5.6.5.3 Type Footprint5.6.5.4 Application Footprint5.6.5.5 Mode Footprint5.7 Company Evaluation Matrix: Startups/SMEs, 20235.7.1 Progressive Companies5.7.2 Responsive Companies5.7.3 Dynamic Companies5.7.4 Starting Blocks5.7.5 Competitive Benchmarking: Startups/SMEs, (2023)5.7.5.1 Detailed List of Key Startups/SMEs5.7.5.2 Competitive Benchmarking of Key Startups/SMEs5.7.6 Valuation and Financial Metrics of Key Microfiltration Membrane Vendors5.8 Competitive Scenario and Trends5.8.1 Product Launches5.8.2 Deals5.8.3 Expansions6 Company Profiles Merck KGaA Sartorius AG Kovalus Separation Solutions Hydranautics (Nitto Denko Company) Pall Corporation 3M Pentair Asahi Kasei Corporation Toray Industries Inc. Veolia Alfa Laval Applied Membranes, Inc. Qua Group LLC Gea Group Aktiengesellschaft Graver Technologies Imemflo Kubota Corporation Mann+Hummel Nx Filtration Bv Parker Hannifin Corp Synder Filtration, Inc. Toshiba Water Solutions Private Limited Nilsan Nishotech Systems Pvt. Ltd. Lenntech B.V. Lydall, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Merck KGaA, 3M, and Danaher Strengthen Medical Filtration Market Leadership Through Strategic Expansions, Spin-Offs, and Mergers
The Medical Filtration Companies Quadrant offers a detailed analysis of the global medical filtration market, spotlighting key players, technological advancements, and market trends. This report categorizes the top 15 companies, including leaders like Merck KGaA, 3M, and Danaher, each excelling in areas such as healthcare and life sciences. Medical filtration is crucial for removing contaminants from fluids, ensuring safety and purity in applications like dialysis and drug delivery. Techniques include microfiltration and ultrafiltration, driven by chronic disease prevalence and regulatory standards. This innovation-rich market is essential for patient safety and product integrity in healthcare. Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Medical Filtration - Company Evaluation Report, 2025" report has been added to Medical filtration Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Medical filtration. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. Over 40 companies were evaluated of which the Top 15 Medical filtration companies were categorized and recognized as the quadrant filtration is crucial for removing contaminants from fluids, including liquids and gases, to ensure safety and purity in medical applications. This market encompasses various filtration techniques, such as microfiltration, ultrafiltration, and nanofiltration, which are vital for infection control and patient safety. The increasing prevalence of chronic diseases and stringent regulatory standards are driving demand for advanced filtration solutions, fueling the market's growth. As a key component in preserving product integrity, medical filtration plays a vital role in the healthcare filtration is widely used in healthcare applications such as dialysis, drug delivery, IV infusion, sterile filtration, endoscopy, sterile processing, and bio-artificial processes, ensuring patient safety and treatment effectiveness. These applications rely on advanced filter materials, including polyethersulfone (PES), polysulfone (PSU), polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), and polypropylene (PP), which provide excellent chemical resistance, biocompatibility, and filtration efficiency. Various filtration technologies, including ultrafiltration (UF), microfiltration (MF), nanofiltration (NF), reverse osmosis (RO), and gas filtration, help eliminate contaminants, bacteria, viruses, and particulates while maintaining the purity of medical fluids and devices. By integrating these filtration solutions, healthcare systems can enhance sterility, optimize fluid purity, and improve overall patient 360 Quadrant maps the Medical filtration companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Medical filtration quadrant. The top criteria for product footprint evaluation included By Material (Polyethersulfone (PES), Polytetrafluoroethylene (PTFE), Polypropylene (PP), Polyvinylidene Fluoride (PVDF), and other materials), By Process Technology (Microfiltration, Ultrafiltration, Nanofiltration, Reverse osmosis, Gas filtration, and others), By Design (Systems (RTU units), filtration modules (consumables), and other process/design filtration solutions), End-User and Players:Merck KGaA (Germany), 3M (Solventum) (US), Danaher (US), Sartorius AG (Germany), Asahi Kasei Corporation (Japan), Baxter (US), Veolia (France), Thermo Fisher Scientific Inc (US), Donaldson Company Inc (US), PARKER HANNIFIN CORP (US), Entegris (US), and MANN+HUMMEL (Germany) are some of the major players in this market. These companies have adopted strategies, such as investments & expansions, product launches, partnerships, agreements, and acquisitions, to maintain their positions in the KGaAMerck KGaA holds a significant position in the medical filtration market, known for its diverse Company Product Portfolio and robust Company Market Share. Based in Germany, the company excels in multiple segments, including Healthcare and Life Sciences, with the Process Solutions unit contributing significantly to its success. Merck's continuous investments, such as expansions in Cork, Ireland, denote its commitment to scaling production capabilities for novel therapies and diagnostics.3M3M has strategically positioned itself through initiatives like the spin-off of its healthcare business, forming Solventum Corporation. This move boosted its focus on medical filtration, enhancing its Company Positioning and Market Share. Known for its Zeta Plus filters, 3M remains a frontrunner in offering scalable, high-efficiency filtration competitive edge is fortified through strategic mergers, showcasing strong Company Analysis and Positioning across its comprehensive Company Product Portfolio. The merger of Cytiva and Pall's life sciences into its operations has enriched Danaher's capacity to deliver biotechnology solutions, marking its presence as a versatile supplier in the Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions & Exclusions1.3 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Increasing Demand for Advanced Healthcare Solutions3.2.1.2 Rising Awareness of Infection Control3.2.1.3 Technological Advancements3.2.2 Restraints3.2.2.1 High Capital Investments3.2.2.2 Stringent Regulatory Compliance3.2.3 Opportunities3.2.3.1 Growing Healthcare Investments in Emerging Economies3.2.3.2 Adoption of Single-Use Technologies3.2.4 Challenges3.2.4.1 Speed and Yield Issues3.3 Porter's Five Forces Analysis3.3.1 Threat of New Entrants3.3.2 Threat of Substitutes3.3.3 Bargaining Power of Suppliers3.3.4 Bargaining Power of Buyers3.3.5 Intensity of Competitive Rivalry3.4 Impact of AI/Gen AI3.5 Value Chain Analysis3.5.1 Raw Material Suppliers3.5.2 Manufacturers3.5.3 Distributors3.5.4 End-users3.6 Ecosystem Analysis3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Microfiltration3.7.1.2 Ultrafiltration3.7.1.3 Nanofiltration3.7.2 Complementary Technologies3.7.2.1 Single-Use Technology3.7.3 Adjacent Technologies3.7.3.1 Chromatography3.8 Trends/Disruptions Impacting Customer Business3.9 Key Conferences and Events, 2025-20263.10 Patent Analysis3.10.1 Introduction3.10.2 Legal Status of Patents3.10.3 Jurisdiction Analysis4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.3 Revenue Analysis, 2021-20234.4 Market Share Analysis, 20234.5 Company Valuation and Financial Metrics4.6 Product Comparison4.7 Company Evaluation Matrix: Key Players, 20234.7.1 Stars4.7.2 Emerging Leaders4.7.3 Pervasive Players4.7.4 Participants4.7.5 Company Footprint: Key Players, 20234.7.5.1 Region Footprint4.7.5.2 Material Footprint4.7.5.3 Process Technology Footprint4.7.5.4 Design/Process Footprint4.7.5.5 Application Footprint4.7.5.6 End-user Footprint4.8 Company Evaluation Matrix: Startups/SMEs, 20234.8.1 Progressive Companies4.8.2 Responsive Companies4.8.3 Dynamic Companies4.8.4 Starting Blocks4.8.5 Competitive Benchmarking: Startups/SMEs, 20234.8.5.1 Detailed List of Key Startups/SMEs4.8.5.2 Competitive Benchmarking of Key Startups/SMEs4.9 Competitive Scenario4.9.1 Product Launches4.9.2 Deals4.9.3 Expansions4.9.4 Other Developments5 Company Profiles - Medical Filtration Equipment Providers5.1 Key Players5.1.1 Merck KGaA5.1.1.1 Business Overview5.1.1.2 Products/Solutions/Services Offered5.1.1.3 Recent Developments5.1.1.3.1 Expansions5.1.1.4 Analyst's View5.1.1.4.1 Right to Win5.1.1.4.2 Strategic Choices5.1.1.4.3 Weaknesses and Competitive Threats5.1.2 3M (Solventum)5.1.3 Danaher5.1.4 Sartorius AG5.1.5 Asahi Kasei Corporation5.1.6 Baxter5.1.7 Thermo Fisher Scientific Inc.5.1.8 Veolia5.1.9 Donaldson Company, Inc.5.1.10 Parker Hannifin Corp5.1.11 Entegris5.1.12 Mann+Hummel5.2 Other Players5.2.1 Corning Incorporated5.2.2 Critical Process Filtration, Inc.5.2.3 Cobetter5.2.4 Graver Technologies5.2.5 Ertelalsop5.2.6 Kasag Swiss AG5.2.7 Filtrox AG5.2.8 Membrane Solutions5.2.9 Cole-Parmer Instrument Company, LLC5.2.10 Meissner Filtration Products, Inc.5.2.11 Medical Filtration Solutions Ltd.5.2.12 Sefar AG5.2.13 Walker Filtration5.2.14 Saint-Gobain For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Malaysian Reserve
4 days ago
- Business
- Malaysian Reserve
G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise
'Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players Like Promega, Thermo Fisher Scientific, and Merck KGaA' BOSTON, July 16, 2025 /PRNewswire/ — According to the latest study from BCC Research, the 'G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets' is expected to grow from $4.4 billion in 2024 to $6.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029. This report provides a comprehensive look at the global market for G protein-coupled receptor (GPCR) targeting technologies. It analyzes current market size and growth trends, and segments the market by assay type, product type application, and region. Assay types include functional and binding assays, while product types range from cell lines to detection kits. Applications span cancer, cardiovascular, CNS, and respiratory diseases. The report also covers regional markets across North America, Europe, Asia-Pacific, and the Rest of the World, and includes company profiles, industry trends, and collaborations. This report is particularly relevant today due to the rapid advances in GPCR targeting technologies, driven by growing research into disease mechanisms and the rise of personalized medicine. GPCRs are key targets in treating major conditions like cancer, neurological, and cardiovascular diseases. With innovations such as AI and allosteric modulation shaping drug discovery, staying informed on these trends helps companies remain competitive and navigate complex regulations in a rapidly evolving market. The factors driving the market's growth include: Rising incidence of chronic diseases: As conditions like heart disease, diabetes, and cancer become more common worldwide, there's a growing need for treatments. GPCRs play a key role in many of these diseases, making them important targets for new drugs. Growing demand for GPCR-targeting drugs: GPCR-targeting drugs are already widely used, and demand is rising. While these drugs are effective for many health issues, there is still a need for better treatments, leading to a push for more R&D in this area. Technological advances in GPCR research: New tools like cryo-EM, AI, and advanced screening methods are making it easier and faster to study GPCRs. These advances help scientists design better drugs with more precision and fewer side effects. Request a sample copy of the global G protein-coupled receptor (GPCR) market report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $4.1 billion Market size forecast $6.1 billion Growth rate CAGR of 6.8% for the forecast period of 2024-2029 Segments covered Assay Type, Product Type, Application, and Region (South America, the Middle East and Africa) Regions covered North America, Asia-Pacific, Europe, Rest of the World Countries covered U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Russia, Japan, India, China, South Korea, Australia, Singapore Market drivers • Rising incidence of chronic diseases. • Growing demand for GPCR-targeting drugs. • Technological advances in GPCR research. Interesting facts: GPCRs and Drug Targets: Over 30% of all marketed drugs target GPCRs, making them one of the most important and druggable protein families in pharmacology. Sensory Functions: GPCRs are essential for senses like vision, taste, and smell playing key roles in the retina and the olfactory system. Diverse and Widespread: Humans have over 800 GPCRs involved in processes from immunity to neurotransmission, linking them to diseases like cancer, heart conditions, and neurological disorders. Emerging startups Confo Therapeutics: This company is developing a proprietary technology to target GPCR conformational changes, opening new therapeutic avenues for treating cancer and neurological diseases. Tectonic Therapeutic: Uses innovative platforms for discovering drugs targeting GPCRs involved in immune and inflammatory diseases, with a focus on immune modulation. Syn Vivo: Specializes in microfluidic platforms and live-cell imaging technologies to provide real-time, high-resolution cell-based assays for drug discovery and research. The report addresses the following questions: What is the projected size and growth rate of the GPCR targeting market?– The global market reached $4.1 billion in 2023 and is expected to reach $6.1 billion by the end of 2029, at a CAGR of 6.8% during the forecast period. Which market segments are covered in the report?– The GPCR targeting market is segmented based on assay type, product type, application, and region. Which product type segment will be dominant through 2029?– Cell lines are anticipated to have the highest market share by the end of 2029. Which region's market is growing the fastest?– Asia-Pacific is the fastest growing market. Market leaders include: AGILENT TECHNOLOGIES INC. BECTON DICKINSON DANAHER CORP. ENZO BIOCHEM INC. EPICS THERAPEUTICS EUROFINS SCIENTIFIC INTERAX BIOTECH AG MERCK KGAA ORION BIOTECHNOLOGY CANADA LTD. PROMEGA CORP. QIAGEN REVVITY TECTONIC THERAPEUTIC THERMO FISHER SCIENTIFIC INC. WUXI APPTEC Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to purchase one, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo –
Yahoo
5 days ago
- Business
- Yahoo
MilliporeSigma Launches AAW™ Workstation to Advance Lab Automation
New platform powered by Opentrons expands lab automation to accelerate scientific discovery Plug-and-play design for effortless integration into diverse laboratory settings Validated protocols across applications benefit academia, pharma, and biotech BURLINGTON, Mass., July 15, 2025--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by Opentrons, a leader in lab automation and accessible robotics. The workstation automates routine laboratory experiments previously performed manually, reducing hands-on time and ensuring consistency in results across diverse experimental settings. This launch follows the earlier announcement of a multi-year partnership with Opentrons Labworks, Inc. to enhance laboratory workflows through automation. "Our customers are increasingly seeking tools that improve efficiency and deliver reliable and reproducible results," said Anand Nambiar, Head of Science & Lab Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. "The AAW™ exemplifies our commitment to equipping scientists with solutions that simplify their workflows and enhance their research capabilities. By automating routine tasks, researchers can focus on solving complex scientific challenges and accelerate discovery." Designed to advance the lab of the future, the AAW™ offers a plug-and-play setup and an extensive library of validated assay protocols across protein, molecular, and cell biology applications. Its versatility and ease of integration make it an ideal fit for academic, biotech, and pharmaceutical labs looking to boost productivity without compromising quality. The AAW™ joins MilliporeSigma's growing portfolio of digital and automation innovations, including: M-Trace® Software: The first software offering complete data traceability in microbial QC. MyMilli-Q™ Services: A digital platform for water purification system oversight, ensuring high-quality water for critical experiments. ChemisTwin® Platform: The first-ever digital reference material platform that confirms compound structures and quantifies samples. For more information about the AAW™ and to explore our full range of innovative solutions, visit About the Life Science business of Merck KGaA, Darmstadt, Germany The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn. All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. About Opentrons Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform, which includes business units Opentrons® Robotics and Neochromosome™. Opentrons has raised over $200 million in funding and achieved unicorn status based on its innovative technologies. The Opentrons Flex® is Opentrons' newest generation of liquid-handling lab robots, offering open-source accessibility and compatibility with generative AI tools. Opentrons Robotics provides thousands of institutions with flexible, easy-to-use lab robots, automating R&D operations and making robotics, a vast open-source library accessible to life sciences researchers worldwide. Opentrons is used in labs at the top 20 academic universities in the US and 14 of 15 leading global biopharmaceutical companies. Learn more at View source version on Contacts Media Relations Phone: +1.314.296.8288 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-07-2025
- Business
- Yahoo
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business sector Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks portfolio and pimicotinib SpringWorks rare tumor portfolio includes Ogsiveo, a first-in-disease systemic therapy for adults with desmoid tumors and Gomekli a first and only approved therapy for adults and children with NF1-PN Not intended for UK-based media DARMSTADT, Germany, July 01, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions. The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks, based in Stamford, Connecticut, was announced on 28 April, 2025. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025. The business combination will immediately contribute to Merck KGaA, Darmstadt, Germany's revenues and is expected to be accretive to the company's earnings per share pre (EPS pre) by 2027. "Today, we officially welcome SpringWorks to Merck KGaA, Darmstadt, Germany. The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck KGaA, Darmstadt, Germany as a globally diversified science and technology powerhouse," said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. "This is the largest acquisition we have made for our Healthcare business sector in nearly 20 years, marking an exciting new chapter for Healthcare. Furthermore, we remain committed to identifying M&A opportunities across our three business sectors, with a focus on Life Science, prioritizing strategic fit, financial robustness, and long-term value creation." "This acquisition is a significant step forward in bringing innovation to patients living with rare and often debilitating tumors—many of whom are young and facing a long, uncertain journey with limited treatment options," said Danny Bar-Zohar, CEO of Healthcare and member of the Executive Board at Merck KGaA, Darmstadt, Germany. "By combining our global reach with SpringWorks' expertise, we are expanding access to life-changing therapies for patients around the world. At the same time, this move strengthens our foundation for further expansion in rare tumors and adjacent disease areas. I'd like to warmly welcome the SpringWorks team to Merck KGaA, Darmstadt, Germany." SpringWorks' portfolio features two highly innovative products for the treatment of rare tumors in areas of high unmet need where limited treatment options exist. U.S. Food and Drug Administration (FDA)-approved, OGSIVEO® (nirogacestat) is a first-in-class therapy for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. In June 2025, the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of nirogacestat. GOMEKLI® (mirdametinib) is the first and only FDA-approved therapy for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. In May 2025, the CHMP adopted a positive opinion recommending the approval of mirdametinib. SpringWorks' portfolio complements Merck KGaA, Darmstadt Germany's progress in building a rare tumor business with Merck KGaA, Darmstadt, Germany having worldwide commercialization rights for pimicotinib, an investigational therapy developed by Abbisko Therapeutics Co., Ltd. for patients with tenosynovial giant cell tumor (TGCT). Global regulatory filings for pimicotinib are underway. The joint portfolio will serve a broad range of patients with rare tumors who have high unmet medical needs. Shares in SpringWorks will no longer be traded on the Nasdaq, with Merck KGaA, Darmstadt, Germany now being the sole owner of SpringWorks. SpringWorks shareholders are being paid US$ 47 per share in cash. *Based on SpringWorks' cash balance as of 31 December 2024 About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to to register online, change your selection or discontinue this service. View source version on Contacts Media Relations Phone: +49 151 1454-9591 Investor Phone: +49 6151 72-3321 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
